Australia's system of HTA decision-making can be imagined as a scramble of one hundred eggs. For the therapies and other technologies that provide better patient outcomes, the review's report proposes adding more eggs to the scramble. For therapies that can deliver savings, the scramble is discarded. …
The HTA Review report - 'Red Flag' number two of five
September 16, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
NSW pharmacists to deliver all childhood vaccines and treat more conditions under reforms
September 11, 2026 - - Latest News -
Rare genetic motor neurone disease treatment finally reaches Australian patients
September 11, 2026 - - Latest News -
Taking a stake is not the same as spectating investor risk and expecting a benefit
September 10, 2026 - - Latest News -
Artificial intelligence in HTA has arrived, kind of, but nobody was thinking of this
September 10, 2026 - - Latest News -
Melbourne oncologist takes the reins at Australia's private cancer physicians body
September 10, 2026 - -
Australia secures sovereign viral vector manufacturing as VVMF wins TGA licence
September 10, 2026 - - Latest News -
Which is it? The two perspectives on patient input compounded by the lack of transparency
September 10, 2026 - - Latest News